Gilead Sciences Beheer

Beheer criteriumcontroles 3/4

De CEO Gilead Sciences is Dan O'Day, benoemd in Mar2019, heeft een ambtstermijn van 4.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 21.62M, bestaande uit 7.8% salaris en 92.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.031% van de aandelen van het bedrijf, ter waarde CHF 26.58M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 5.1 jaar.

Belangrijke informatie

Dan O'Day

Algemeen directeur

US$21.6m

Totale compensatie

Percentage CEO-salaris	7.8%
Dienstverband CEO	4.5yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Dan O'Day's beloning veranderd ten opzichte van Gilead Sciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

Compensatie versus markt: De totale vergoeding ($USD 21.62M ) Dan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 4.73M ).

Compensatie versus inkomsten: De vergoeding van Dan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Dan O'Day (59 yo)

4.5yrs

Tenure

US$21,621,253

Compensatie

Mr. Daniel P. O'Day, also known as Dan, serves as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019. He served as Member of Supervisory Board at Galapagos NV since October 22,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel P. O'Day	Chairman & CEO	4.5yrs	US$21.62m	0.031% CHF 26.6m
Andrew Dickinson	Executive VP & CFO	3.8yrs	US$8.40m	0.0088% CHF 7.6m
Deborah Telman	Executive VP of Corporate Affairs	1.1yrs	US$4.82m	0.00052% CHF 448.8k
Johanna Mercier	Chief Commercial Officer	4.2yrs	US$9.24m	0.0072% CHF 6.2m
Merdad Parsey	Chief Medical Officer	3.8yrs	US$9.04m	0.0056% CHF 4.9m
Sandra Patterson	Senior VP	less than a year	geen gegevens	0.0024% CHF 2.1m
Jacquie Ross	Vice President of Investor Relations	2.7yrs	geen gegevens	geen gegevens
Jyoti Mehra	Executive Vice President of Human Resources	4.1yrs	geen gegevens	geen gegevens
Michael Quigley	Senior Vice President of Research Biology	3.6yrs	geen gegevens	geen gegevens
Linda Higgins	Senior Vice President of Research	3.6yrs	geen gegevens	geen gegevens
Rudolf Ertl	Senior Vice President of Commercial Operations of Australia	no data	geen gegevens	geen gegevens
Flavius Martin	Executive Vice President of Research	2.4yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 000935700 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel P. O'Day	Chairman & CEO	4.5yrs	US$21.62m	0.031% CHF 26.6m
Anthony Welters	Independent Director	2.9yrs	US$429.93k	0.00064% CHF 552.4k
Paul Berg	Member of Scientific Advisory Board	no data	US$16.00k	geen gegevens
Jacqueline Barton	Independent Director	5.7yrs	US$414.88k	0.0018% CHF 1.5m
Eugene Schiff	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Mellors	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Francis Chisari	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Paul Klotman	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kevin Lofton	Lead Independent Director	14.2yrs	US$489.93k	0.0074% CHF 6.4m
Kelly Kramer	Independent Director	7.1yrs	US$434.93k	0.00011% CHF 94.9k
Joel Huff	Chairperson of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Grace Colon	Chairman of the Board	less than a year	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 000935700 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).

Gilead Sciences Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Recent updates

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd